(NASDAQ: TBPH) Theravance Biopharma's forecast annual revenue growth rate of 19.32% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.13%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.77%.
Theravance Biopharma's revenue in 2025 is $65,266,000.On average, 3 Wall Street analysts forecast TBPH's revenue for 2025 to be $4,827,928,613, with the lowest TBPH revenue forecast at $4,800,127,872, and the highest TBPH revenue forecast at $4,878,629,963. On average, 3 Wall Street analysts forecast TBPH's revenue for 2026 to be $4,195,611,768, with the lowest TBPH revenue forecast at $4,100,109,224, and the highest TBPH revenue forecast at $4,285,614,166.
In 2027, TBPH is forecast to generate $5,939,808,232 in revenue, with the lowest revenue forecast at $5,698,651,808 and the highest revenue forecast at $6,420,671,042.